Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · June 07, 2022

Clazakizumab for the Treatment of COVID-19 Pneumonia With Hyperinflammation

Critical Care Medicine

 

Additional Info

Disclosure statements are available on the authors' profiles:

Critical Care Medicine
A Randomized Double-Blinded Placebo Controlled Trial of Clazakizumab for the Treatment of COVID-19 Pneumonia With Hyperinflammation
Crit. Care Med. 2022 May 18;[EPub Ahead of Print], BE Lonze, P Spiegler, RN Wesson, N Alachkar, E Petkova, EP Weldon, RA Dieter, Y Li, M Quinn, A Mattoo, I Soomro, SM Cohen, S Leung, CL Deterville, BM Landrum, MI Ali, DJ Cohen, AL Singer, A Sen, E Chong, JS Hochman, AB Troxel, RA Montgomery

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading